Joshua Froess

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Symptoms and Impaired Quality of Life After COVID-19 Hospitalization: Effect of Therapeutic Heparin in Non-ICU Patients in the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 Acute Trial”.

Symptoms and Impaired Quality of Life After COVID-19 Hospitalization: Effect of Therapeutic Heparin in Non-ICU Patients in the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 Acute Trial

CHEST Journal(2023)10.1016/j.chest.2023.11.019

N/A

0.216DataRank · unranked

3 citations

Kinsley Hubel, Joshua Froess, Stephen R. Wisniewski, Vidya Venugopal, Yu‐Hsuan Lai +23 more

Effect of P2Y12 Inhibitors on Organ Support–Free Survival in Critically Ill Patients Hospitalized for COVID-19

JAMA Network Open(2023)10.1001/jamanetworkopen.2023.14428

N/A

0DataRank · unranked

17 citations

Matthew D. Neal, Lucy Z. Kornblith, Michelle N. Gong, Harmony R. Reynolds, Mary Cushman +72 more

On-Treatment Change in d -Dimer Is Associated With Differential Outcomes Among Therapeutic Dose Heparin-Treated Noncritically Ill Patients Hospitalized for COVID-19

Arteriosclerosis Thrombosis and Vascular Biology(2024)10.1161/atvbaha.124.321108

N/A

0DataRank · unranked

0 citations

Joshua Froess, Thomas L. Ortel, Ryan Zarychanski, Jeffrey S. Berger, Mary Cushman +11 more